DK0777490T3 - Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans - Google Patents

Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans

Info

Publication number
DK0777490T3
DK0777490T3 DK95928662T DK95928662T DK0777490T3 DK 0777490 T3 DK0777490 T3 DK 0777490T3 DK 95928662 T DK95928662 T DK 95928662T DK 95928662 T DK95928662 T DK 95928662T DK 0777490 T3 DK0777490 T3 DK 0777490T3
Authority
DK
Denmark
Prior art keywords
effective
enterotoxin
oral adjuvant
toxic oral
mutant enterotoxin
Prior art date
Application number
DK95928662T
Other languages
Danish (da)
English (en)
Inventor
John D Clements
Bonny L Dickinson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of DK0777490T3 publication Critical patent/DK0777490T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95928662T 1994-08-26 1995-07-18 Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans DK0777490T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant

Publications (1)

Publication Number Publication Date
DK0777490T3 true DK0777490T3 (da) 2006-09-18

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95928662T DK0777490T3 (da) 1994-08-26 1995-07-18 Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans

Country Status (22)

Country Link
US (2) US6019982A (zh)
EP (1) EP0777490B1 (zh)
JP (1) JP3860208B2 (zh)
KR (1) KR100399258B1 (zh)
CN (1) CN1182868C (zh)
AT (1) ATE326231T1 (zh)
AU (1) AU709779B2 (zh)
BR (1) BR9508633A (zh)
CA (1) CA2198586C (zh)
CZ (1) CZ298131B6 (zh)
DE (1) DE69534992T2 (zh)
DK (1) DK0777490T3 (zh)
ES (1) ES2265148T3 (zh)
FI (1) FI120137B (zh)
HU (1) HU222985B1 (zh)
NO (1) NO317942B1 (zh)
NZ (1) NZ291262A (zh)
PL (1) PL182667B1 (zh)
PT (1) PT777490E (zh)
RU (1) RU2160606C2 (zh)
WO (1) WO1996006627A1 (zh)
ZA (1) ZA956412B (zh)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP0967279B1 (en) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
AU7788194A (en) 1993-10-05 1995-05-01 Medeva Holdings B.V. Vaccine compositions
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
AU696941B2 (en) * 1994-07-01 1998-09-24 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
EP0909323B1 (en) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
AU7410798A (en) * 1996-11-29 1998-06-22 General Hospital Corporation, The Heterologous antigens in live cell V
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CA2297374A1 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
WO2000051634A1 (fr) * 1999-03-03 2000-09-08 The Kitasato Institute Preparations de vaccins contenant des acides gras comme composants
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US7722887B1 (en) * 1999-09-15 2010-05-25 Mogam Biotechnology Research Institute Detoxified mutants of escherichia coli heat-labile enterotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ES2462532T3 (es) * 1999-10-18 2014-05-23 Novartis Vaccines And Diagnostics, Inc. Composiciones y métodos para estimular una respuesta inmune contra agentes infecciosos
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
ATE357461T1 (de) 2000-08-25 2007-04-15 Aventis Pasteur Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
CA2420601A1 (en) * 2000-08-31 2003-02-26 The Kitasato Institute Vaccine preparation containing fatty acid as component
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
AU2002252378B2 (en) 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
JP2005538954A (ja) * 2002-05-31 2005-12-22 トーマス・ジェファーソン・ユニバーシティ 分子の経上皮輸送用組成物及び方法
EP1551451B1 (en) * 2002-08-27 2009-02-25 Dow AgroSciences LLC Use of escherichia coli heat labile toxin as an adjuvant in poultry
AU2003278496A1 (en) * 2002-11-14 2004-06-03 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
EP2272532B1 (en) 2003-09-02 2016-02-10 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine
WO2005079841A2 (en) * 2003-12-09 2005-09-01 Iomai Corporation Gm1 binding deficient exotoxins for use as immunoadjuvants
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
US20090068218A1 (en) * 2005-09-09 2009-03-12 Universitat Zurich Antigens for Vaccination Against and Detection of Mycoplasma Suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
WO2007098607A1 (en) 2006-03-03 2007-09-07 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8329195B2 (en) 2007-05-23 2012-12-11 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
BRPI0721746B1 (pt) * 2007-07-18 2021-08-31 Development Center For Biotechnology Polipeptídeo isolado, vacina, ácido nucléico isolado, vetor e células transformadas de bactérias e fungos
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2528648T3 (es) 2007-09-11 2015-02-11 University Of Guelph Inmunógenos polisacáridos de la Clostridium Difficile
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
BRPI0910168A2 (pt) * 2008-07-01 2019-09-24 Univ George Washington "vacina anti-helmíntica multivalente e método de vacinar um indivíduo em necessidade da mesma contra infecção por ancilóstomo e esquistossomose"
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
JP6014666B2 (ja) 2012-06-20 2016-10-25 国立大学法人 東京大学 粘膜免疫賦活化剤及びｈｐｖ感染症治療用経口医薬組成物
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Also Published As

Publication number Publication date
HUT77869A (hu) 1998-09-28
CZ56297A3 (en) 1997-10-15
NZ291262A (en) 1999-02-25
US6440423B1 (en) 2002-08-27
BR9508633A (pt) 1997-09-30
US6019982A (en) 2000-02-01
PL182667B1 (pl) 2002-02-28
ES2265148T3 (es) 2007-02-01
CN1182868C (zh) 2005-01-05
ZA956412B (en) 1996-03-11
EP0777490A1 (en) 1997-06-11
CA2198586A1 (en) 1996-03-07
FI120137B (fi) 2009-07-15
HU222985B1 (hu) 2004-01-28
CZ298131B6 (cs) 2007-07-04
NO970993L (no) 1997-04-25
DE69534992D1 (de) 2006-06-22
EP0777490A4 (en) 1998-11-18
RU2160606C2 (ru) 2000-12-20
PL318930A1 (en) 1997-07-21
ATE326231T1 (de) 2006-06-15
NO970993D0 (no) 1997-03-04
CA2198586C (en) 2010-10-12
JP3860208B2 (ja) 2006-12-20
AU3233795A (en) 1996-03-22
DE69534992T2 (de) 2007-05-10
NO317942B1 (no) 2005-01-10
PT777490E (pt) 2006-10-31
AU709779B2 (en) 1999-09-09
WO1996006627A1 (en) 1996-03-07
JPH10505059A (ja) 1998-05-19
FI970799A0 (fi) 1997-02-26
CN1164191A (zh) 1997-11-05
KR970705403A (ko) 1997-10-09
KR100399258B1 (ko) 2003-12-31
EP0777490B1 (en) 2006-05-17
MX9701445A (es) 1998-05-31
FI970799A (fi) 1997-04-24

Similar Documents

Publication Publication Date Title
DK0777490T3 (da) Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
DE69421939D1 (de) Nichttoxisches schleimhautadjuvans
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
DE69304521D1 (de) Impfstoff Adjuvans
AU2147992A (en) Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
EE03016B1 (et) Peroraalselt manustatav ravimvorm tsentraalse dopamiinipuuduse-seisundi ravimiseks ja selle valmistamise meetod
CA2022420A1 (en) Escherichia coli vaccine
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
DK0725653T3 (da) Vaccinepræparater
DE60031243D1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
HU9401400D0 (en) New bacterium causing poultry disease and vaccine derived thereof
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
EA200300557A1 (ru) Комбинированные композиции адъювантов
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
Vetkova et al. Protective effect of Pseudomonas aeruginosa polyvalent corpuscular vaccine in P. aeruginosa generalized chronic infection of mice with cyclophosphamide-induced leukopenia.